Tenon Medical (NASDAQ: TNON), a medical device company focused on treating sacroiliac (SI) joint disorders, has acquired sacro-pelvic fusion assets from SiVantage, including its SImmetry® and SImmetry+™ technologies. This strategic acquisition transforms Tenon into a multi-product, multi-approach sacro-pelvic organization, offering a broader portfolio for varying patient anatomies.
In conjunction with the technology transfer, SiVantage co-founders Wyatt Geist and Nate Grawey will join Tenon’s leadership team as Chief Innovations Officer and Chief Commercial Officer, respectively, enhancing Tenon’s commercial and innovation capabilities.
The deal is structured with an upfront cash payment and equity issuance, while the majority of the total consideration is tied to future performance milestones. The full integration is expected to be completed by Q4 2025.
Tenon expects the newly acquired technologies to contribute immediately to revenue, supported by extensive clinical data demonstrating safety and performance in SI joint fusion procedures.
By combining the Catamaran® system with SImmetry® and SImmetry+™, Tenon now offers multiple surgical approaches for sacro-pelvic fixation, giving surgeons flexibility and innovation in treating SI joint disorders. The company believes this expanded portfolio positions it to address a growing market with underserved demand and strong potential for growth.
The post Tenon Medical Acquires SiVantage Assets to Expand Sacro-Pelvic Fusion Capabilities appeared first on PRISM MarketView.
